The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Adaptimmune; Daiichi Sankyo; Pfizer; Plexxikon
Speakers' Bureau - Adaptimmune; Caris Centers of Excellence; Janssen; Lilly
Research Funding - Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - N/A

ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Agios; Blueprint Medicines; Daiichi Sankyo; Eisai; EMD Serono; GlaxoSmithKline; Immune Design; Janssen; Lilly; Loxo; Nanocell Therapy; Novartis; Plexxikon
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Methods of Treating Metastatic Sarcoma Using Talimogene Laherparepvec (T-Vec) and Pembrolizumab Combination Therapy- 62/671,625
 
Andrew J. Wagner
Honoraria - Novartis
Consulting or Advisory Role - Daiichi Sankyo; Five Prime Therapeutics; Lilly; Loxo
Research Funding - AADi (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
 
Zsuzsanna Papai
No Relationships to Disclose
 
Kristen N. Ganjoo
Consulting or Advisory Role - Daiichi Sankyo; Immune Design; Janssen; Lilly; Novartis
 
Chueh-Chuan Yen
Honoraria - Amgen; Eisai; Lilly; Merck Sharp & Dome
Consulting or Advisory Role - Lilly; Merck Sharp & Dome
Research Funding - Efficient Pharma Management Corp.; Eisai; Lilly; Ono Pharmaceutical; TLC PharmaChem
Travel, Accommodations, Expenses - Merck Sharp & Dome; Ono Pharmaceutical; Roche
 
Patrick Schoffski
Consulting or Advisory Role - Adaptimmune (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Intellisphere (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Plexxikon (Inst); SERVIER (Inst); Transgene (Inst)
Research Funding - Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); CoBioRes NV (Inst); Eisai (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Plexxikon (Inst)
 
Albiruni Ryan Abdul Razak
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Merck
Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CASI Pharmaceuticals; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics; Lilly; MedImmune; Merck; Novartis; Pfizer; Roche/Genentech
 
Javier Martin Broto
Honoraria - Lilly; PharmaMar
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Novartis; PharmaMar
Speakers' Bureau - PharmaMar
Research Funding - Eisai (Inst); GlaxoSmithKline; Lilly (Inst); Novartis (Inst); PharmaMar
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar
 
Alexander I. Spira
Honoraria - AstraZeneca/MedImmune; CytomX Therapeutics; Merck
Consulting or Advisory Role - Array BioPharma (Inst)
Research Funding - Abbvie (Inst); Archer (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Akira Kawai
Honoraria - Eisai; Lilly; Novartis; Taiho Pharmaceutical; Takara Bio
 
Anders Krarup-Hansen
No Relationships to Disclose
 
Axel Le Cesne
Honoraria - Amgen; Bayer; Lilly; Novartis; Pfizer; PharmaMar
 
Brian Van Tine
No Relationships to Disclose
 
Yoichi Naito
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; Lilly; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Bayer; Chugai Pharma; Lilly; Meiji Seika Kaisha; Merck Serono; Nippon Kayaku; Novartis; Pfizer; Roche; Taiho Pharmaceutical
Research Funding - Roche
 
Se Hoon Park
Consulting or Advisory Role - Lilly
 
Victoria Soldatenkova
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Gary Mo
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - ImClone LCC, wholly owned subsidiary of Eli Lilly and Company; Lilly
 
Ashwin Shahir
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Jennifer Wright
Employment - Lilly
 
Robin Lewis Jones
Consulting or Advisory Role - Adaptimmune; Blueprint Medicines; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Lilly; Merck Serono; Morphotek; PharmaMar; TRACON Pharma
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar